TLR3 and cancer: Of significance to the aberrant immune responses observed in ME/CFS [34, 35] is a recent seminal observation in cancer that rintatolimod increases the ratio of Teff/Treg cells in the tumor microenvironment, in contrast to non-restricted dsRNA TLR3 agonists [33].